Trial Profile
Scheduling nabpaclItaxEl with GEmcitabine (SIEGE): Randomised phase II trial to investigate two different schedules of nabpaclitaxel (Abraxane) combined with gemcitabine as first line treatment for metastatic pancreatic ductal adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2023
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms SIEGE
- 22 Feb 2023 Results of Clinical and biological markers predictive of treatment response associated with metastatic pancreatic adenocarcinoma, published in the British Journal of Cancer
- 30 Apr 2020 Results published in the British Journal of Cancer
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress.